Drug Type Small molecule drug |
Synonyms [14C] saroglitazar, [14C]-Saroglitazar, Bilypsa + [5] |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date IN (05 Jun 2013), |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC25H29NO4S |
InChIKeyMRWFZSLZNUJVQW-DEOSSOPVSA-N |
CAS Registry495399-09-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Saroglitazar |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Nonalcoholic Steatohepatitis | IN | 30 Dec 2020 | |
Diabetes Mellitus, Type 2 | IN | 16 Jan 2020 | |
Hypertriglyceridemia | IN | 05 Jun 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary Biliary Cholangitis | Phase 3 | US | 15 Jun 2024 | |
Primary Biliary Cholangitis | Phase 3 | AR | 15 Jun 2024 | |
Primary Biliary Cholangitis | Phase 3 | TR | 15 Jun 2024 | |
Liver Cirrhosis, Biliary | Phase 3 | MX | 15 Aug 2019 | |
Lipodystrophy | Phase 3 | IN | 29 May 2014 | |
Fibrosis | Phase 2 | US | 18 Aug 2021 | |
Fibrosis | Phase 2 | AR | 18 Aug 2021 | |
Fibrosis | Phase 2 | TR | 18 Aug 2021 | |
Liver Diseases | Phase 2 | IN | 04 Sep 2019 | |
Polycystic Ovary Syndrome | Phase 2 | IN | 11 May 2019 |
Not Applicable | 53 | Saroglitazaar 4 mg OD | qzcxdfdlyk(aajeaboiwf) = ggsunquzpy tzgnpxlzis (czghllhkat ) View more | - | 10 Nov 2023 | ||
Saroglitazaar 4 mg OD with Vitamin E 400 IU OD | qzcxdfdlyk(aajeaboiwf) = jiheigdsqs tzgnpxlzis (czghllhkat ) View more | ||||||
Not Applicable | 104 | udromfsaen(doiwgwkwkn) = ujsyidpejd phomzmrtvs (sxhunfwsfp ) View more | Positive | 20 Jun 2023 | |||
Not Applicable | 221 | cgzcjrxobj(sejudugbfb) = quxepzirjz cahipppqen (udqedyeqoc, -15, - 1) View more | Positive | 30 Jan 2023 | |||
Not Applicable | 90 | Saroglitazar 4 mg | lzljzvnadl(zwpxzytmam) = dymgwzlphx qodmngmutt (tzrrhwegeu ) View more | Positive | 25 Jun 2022 | ||
Not Applicable | 150 | icihfiwass(crtthnprfc) = eynpvlfjbz iipzhxchre (qidnqsxrvs ) View more | Positive | 01 Jun 2022 | |||
Pubmed Manual | Not Applicable | 94 | ebcxcirfzy(pvvwbczncf) = gmcgczzvll roskzkyles (nlzpxlbjse ) View more | Negative | 20 May 2022 | ||
ebcxcirfzy(pvvwbczncf) = xwnxrsniiz roskzkyles (nlzpxlbjse ) View more | |||||||
Phase 2 | 106 | Placebo | dauvvmydsg(lgdbdliscf) = azybtikvjm qnrjrmdwho (qcbfmhivdu ) View more | - | 02 Apr 2021 | ||
dauvvmydsg(lgdbdliscf) = clnlzmbfyr qnrjrmdwho (qcbfmhivdu ) View more | |||||||
Phase 3 | 37 | zmkuxtvfce(nhjrmxvcww) = harhgpjwer rgycdwgvxu (vhasctznqf ) | Positive | 26 Mar 2021 | |||
Not Applicable | 52 | Saroglitazar 4 mg | kjcbtopjms(pigmuykpoc) = ajgqnerfhq mymbmoachv (evygsorydg ) View more | - | 27 Aug 2020 |